Can less frequent dosing cut costs without sacrificing myeloma control?
NCT ID NCT07485647
First seen Mar 24, 2026 · Last updated May 20, 2026 · Updated 12 times
Summary
This study tests whether giving the drug daratumumab less often (every 8 weeks, then every 16 weeks) along with lenalidomide can control multiple myeloma as well as the standard every-4-week schedule after a stem cell transplant. The goal is to reduce treatment costs and clinic visits while keeping the disease in check. About 50 adults with newly diagnosed multiple myeloma who have responded well to transplant will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37203, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.